Sales & Marketing

Collaboration based on Valo’s large human dataset and computation powered by artificial intelligence.

Deal comes amid previous exclusive marketing agreement.

Company brings aboard former Pfizer exec as life sciences COO in effort to help further improve patient outcomes.

Project to focus on improving access to EstroGel.

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.

Deal to focus on development and commercialization in key emerging countries.

Medicine indicated for patients aged 12 and older.

Celexor Bio expected to focus on ell depletion of pathologic cells in autoimmune and inflammatory disorders.

Agency cites a need for more research to be completed.

Deal aims to provide diabetes treatment to patients across the continent.

Acquisition offers 300 new employees and a bigger product portfolio.

Deal includes all company assets.

Apretude indicated for high-risk adults and adolescents over 12.

Deal features 11 brands including Frisium and Gardenal.

A panel at the recent Talk Health event in Philadelphia focused on what success looks like in audio from publisher, vendor, and HCP perspectives.

Theoria Technologies founded to build dementia ecosystem.

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Bacteria killer signals a milestone—and momentum—for microbiome therapeutics.

Injection buys valuable time to formulate care game plans in diabetes management.

Ushering in a novel class of drugs that attacks HIV at multiple stages of replication.

First-of-its-kind treatment offers hope in the fight against rare heart disease.

Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.

Ebola Zaire vaccine now includes children aged one and older.

Teams aim to develop numerous degrader-antibody conjugates to selectively kill cancer cells.

Company aims to improve access to WHO-recommended pediatric regimen for children with HIV in low- and middle-income countries.